Fluorescently labeled bevacizumab in human breast cancer: defining the classification threshold

Maximilian Koch; Johannes S. de Jong; Jürgen Glatz; Panagiotis Symvoulidis; Laetitia E. Lamberts; Arthur L. L. Adams; Mariëtte E. G. Kranendonk; Anton G. T. Terwisscha van Scheltinga; Michaela Aichler; Liesbeth Jansen; Jakob de Vries; Marjolijn N. Lub-de Hooge; Carolien P. Schröder; Annelies Jorritsma-Smit; Matthijs D. Linssen; Esther de Boer; Bert van der Vegt; Wouter B. Nagengast; Sjoerd G. Elias; Sabrina Oliveira; Arjen J. Witkamp; Willem P. Th. M. Mali; Elsken Van der Wall; P. Beatriz Garcia-Allende; Paul J. van Diest; Elisabeth G. E. de Vries; Axel Walch; Gooitzen M. van Dam; Vasilis Ntziachristos

doi:10.1117/12.2286062

28 July 2017 Fluorescently labeled bevacizumab in human breast cancer: defining the classification threshold

Maximilian Koch, Johannes S. de Jong, Jürgen Glatz, Panagiotis Symvoulidis, Laetitia E. Lamberts, Arthur L. L. Adams, Mariëtte E. G. Kranendonk, Anton G. T. Terwisscha van Scheltinga, Michaela Aichler, Liesbeth Jansen, Jakob de Vries, Marjolijn N. Lub-de Hooge, Carolien P. Schröder, Annelies Jorritsma-Smit, Matthijs D. Linssen, Esther de Boer, Bert van der Vegt, Wouter B. Nagengast, Sjoerd G. Elias, Sabrina Oliveira, Arjen J. Witkamp, Willem P. Th. M. Mali, Elsken Van der Wall, P. Beatriz Garcia-Allende, Paul J. van Diest, Elisabeth G. E. de Vries, Axel Walch, Gooitzen M. van Dam, Vasilis Ntziachristos

Author Affiliations +

Proceedings Volume 10411, Clinical and Preclinical Optical Diagnostics; 104110F (2017) https://doi.org/10.1117/12.2286062
Event: European Conferences on Biomedical Optics, 2017, Munich, Germany

Abstract

In-vivo fluorescently labelled drug (bevacizumab) breast cancer specimen where obtained from patients. We propose a new structured method to determine the optimal classification threshold in targeted fluorescence intra-operative imaging.

Citation Download Citation

Maximilian Koch, Johannes S. de Jong, Jürgen Glatz, Panagiotis Symvoulidis, Laetitia E. Lamberts, Arthur L. L. Adams, Mariëtte E. G. Kranendonk, Anton G. T. Terwisscha van Scheltinga, Michaela Aichler, Liesbeth Jansen, Jakob de Vries, Marjolijn N. Lub-de Hooge, Carolien P. Schröder, Annelies Jorritsma-Smit, Matthijs D. Linssen, Esther de Boer, Bert van der Vegt, Wouter B. Nagengast, Sjoerd G. Elias, Sabrina Oliveira, Arjen J. Witkamp, Willem P. Th. M. Mali, Elsken Van der Wall, P. Beatriz Garcia-Allende, Paul J. van Diest, Elisabeth G. E. de Vries, Axel Walch, Gooitzen M. van Dam, and Vasilis Ntziachristos "Fluorescently labeled bevacizumab in human breast cancer: defining the classification threshold", Proc. SPIE 10411, Clinical and Preclinical Optical Diagnostics, 104110F (28 July 2017); https://doi.org/10.1117/12.2286062

ACCESS THE FULL ARTICLE

INSTITUTIONAL
Select your institution to access the SPIE Digital Library.

SELECT YOUR INSTITUTION

PERSONAL
Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.

PERSONAL SIGN IN

No SPIE Account? Create one

PURCHASE THIS CONTENT

SUBSCRIBE TO DIGITAL LIBRARY

50 downloads per 1-year subscription

Members: $195

Non-members: $335 ADD TO CART

25 downloads per 1 - year subscription

Members: $145

Non-members: $250 ADD TO CART

PURCHASE SINGLE ARTICLE

Includes PDF, HTML & Video, when available